Systematic analysis of the biological roles and pharmacological properties of D-chiro-inositol

Cover Page
  • Authors: Gromova O.A.1,2, Torshin I.Y.1,2, Uvarova E.V.3,4, Tapilskaya N.I.5,6, Kalacheva A.G.7
  • Affiliations:
    1. Federal Research Center «Computer Science and Management»
    2. Lomonosov Moscow State University
    3. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
    4. Sechenov First Moscow State Medical University (Sechenov University)
    5. Ott Research Institute of Obstetrics, Gynecology and Reproductology
    6. Saint Petersburg State Paediatric Medical University
    7. Ivanovo State Medical Academy
  • Issue: Vol 22, No 3 (2020)
  • Pages: 21-28
  • Section: REVIEW
  • URL: https://gynecology.orscience.ru/2079-5831/article/view/34975
  • DOI: https://doi.org/10.26442/20795696.2020.3.200210
  • Cite item

Abstract


D-chiroinositol (DCI) is one of the 9 inositol isomers that forms inositol phosphoglycans, which are mediators of the action of insulin. The metabolism of DCI and myo-inositol (MI) is impaired against the background of insulin resistance, including the patients with polycystic ovary syndrome (PCOS).

Aim. Highlight the most characteristic pharmacological properties of DCI.

Materials and methods. Systematic computer analysis of 45 600 publications on the biological roles of inositol by methods of the topological theory of pattern recognition and systems biology analysis of human proteome.

Results. A complex of interactions between metabolic disorders of DCI, PCOS, ovulation disorders, obesity associated with numerous hormonal disorders is described. Supplements with DCI and MI increase the sensitivity of cells to insulin and normalize the metabolism of androgens. An important difference between DCI and MI is the presence of DCI in the composition of inositol phosphoglycans that mediate the action of insulin on cells, as well as its participation in the realization of the therapeutic effects of metformin. The use of the MI+DCI combination allows achieving positive dynamics in reducing excess body weight, normalizing blood lipids, glucose and insulin levels, restoring the ovulatory menstrual cycle, improving oocyte quality, and helps prevent gestational diabetes in pregnant women and macrosomia of the fetus. DCI is more effective than MI in reducing the risk of folate-resistant neural tube defects.

Conclusion. The therapeutic potential of DCI in combination with MI for treating PCOS and hyperandrogenism is evident. Depending on the therapeutic expediency, various ratios of MI:DCI can be used for the treatment of PCOS and disorders of carbohydrate and lipid metabolism.A


Full Text

Restricted Access

About the authors

Olga A. Gromova

Federal Research Center «Computer Science and Management»; Lomonosov Moscow State University

Author for correspondence.
Email: unesco.gromova@gmail.com
ORCID iD: 0000-0002-7663-710X
SPIN-code: 6317-9833
Scopus Author ID: 7003589812

Russian Federation, Moscow

D. Sci. (Med.), Prof

Ivan Yu. Torshin

Federal Research Center «Computer Science and Management»; Lomonosov Moscow State University

Email: unesco.gromova@gmail.com
ORCID iD: 0000-0002-2659-7998
SPIN-code: 1375-1114
Scopus Author ID: 7003300274

Russian Federation, Moscow

Cand. Sci. (Phys.-Math.), Cand. Sci. (Chem.)

Elena V. Uvarova

Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; Sechenov First Moscow State Medical University (Sechenov University)

Email: unesco.gromova@gmail.com

Russian Federation, Moscow

D. Sci. (Med.), Prof

Natalya I. Tapilskaya

Ott Research Institute of Obstetrics, Gynecology and Reproductology; Saint Petersburg State Paediatric Medical University

Email: unesco.gromova@gmail.com
ORCID iD: 0000-0001-5309-0087

Russian Federation, Saint Petersburg

D. Sci. (Med.), Prof.

Alla G. Kalacheva

Ivanovo State Medical Academy

Email: alla_kalacheva@mail.ru
ORCID iD: 0000-0001-6144-5781

Russian Federation, Ivanovo

Cand. Sci. (Med.)

References

  1. Unfer V, Nestler JE, Kamenov ZA et al. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. Int J Endocrinol 2016; 2016: 1849162. doi: 10.1155/2016/1849162
  2. Громова О.А., Торшин И.Ю., Гришина Т.Р. и др. Систематический анализ молекулярно-физиологических эффектов миоинозитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013; 28: 32–41.
  3. [Gromova O.A., Torshin I.Yu., Grishina T.R. et al. Systematic analysis of the molecular physiological effects of myoinositol: data from molecular biology, experimental and clinical medicine. Effective pharmacotherapy. 2013; 28: 32–41 (in Russian).]
  4. Громова О.А., Торшин И.Ю., Калачева А.Г., Тетруашвили Н.К. Роли мио-инозитола в поддержании репродуктивного здоровья женщины. Повышение эффективности технологий экстракорпорального оплодотворения. РМЖ. Мать и дитя. 2018; 1 (1): 88–95. doi: 10.32364/2618-8430-2018-1-1-88-95
  5. [Gromova O.A., Torshin I.Yu., Kalacheva A.G. et al. The role of myo-inositol in maintaining the reproductive health of women. Improving the effectiveness of in vitro fertilization technologies. Breast cancer. Mother and Child 2018; 1 (1): 88–95. doi: 10.32364/2618-8430-2018-1-1-88-95 (in Russian).]
  6. Thomas MP, Mills SJ, Potter BV. The «Other» Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry). Angew Chem Int Ed Engl 2016; 55 (5): 1614–50. doi: 10.1002/anie.201502227
  7. Vitagliano A, Saccone G, Cosmi E et al. Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2019; 299 (1): 55–68. doi: 10.1007/s00404-018-5005-0
  8. Giménez-Bastida JA, Zieliński H. Buckwheat as a Functional Food and Its Effects on Health. J Agric Food Chem 2015; 63 (36): 7896–913. doi: 10.1021/acs.jafc.5b02498
  9. Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of recognition and classification problems. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (2): 274.
  10. Torshin I.Yu., Rudakov K.V. On metric spaces arising during formalization of problems of recognition and classification. Part 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016; 26 (3): 483–96.
  11. Torshin I.Yu. Optimal Dictionaries output information based on the criterion of Solvability and their applications in Bioinformatics. Pattern Recognition and Image Analysis 2013; 23 (2): 319–27.
  12. Torshin I.Yu., Rudakov K.V. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017; 27 (2): 184–99.
  13. Jeon Y, Aja S, Ronnett GV, Kim EK. D-chiro-inositol glycan reduces food intake by regulating hypothalamic neuropeptide expression via AKT-FoxO1 pathway. Biochem Biophys Res Commun 2016; 470 (4): 818–23. doi: 10.1016/j.bbrc.2016.01.115
  14. Hada B, Yoo MR, Seong KM et al. D-chiro-inositol and pinitol extend the life span of Drosophila melanogaster. J Gerontol A Biol Sci Med Sci 2013; 68 (3): 226–34. doi: 10.1093/gerona/gls156
  15. Laganà AS, Unfer V. D-Chiro-Inositol’s action as aromatase inhibitor: rationale and potential clinical targets. Eur Rev Med Pharmacol Sci 2019; 23 (24): 10575–6. doi: 10.26355/eurrev_201912_19752
  16. Larner J. D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work. IUBMB Life 2001; 51 (3): 139–48. doi: 10.1080/152165401753544205
  17. Rendle PM, Kassibawi F, Johnston KA et al. Synthesis and biological activities of d-chiro-inositol analogues with insulin-like actions. Eur J Med Chem 2016; 122: 442–51. doi: 10.1016/j.ejmech.2016.06.047
  18. Larner J. D-chiro-inositol – its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3 (1): 47–60. doi: 10.1080/15604280212528
  19. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Dis 2010; 8 (2): 127–36. doi: 10.1089/met.2009.0052
  20. Ostlund RE Jr, Seemayer R, Gupta S et al. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. J Biol Chem 1996; 271 (17): 10073–8. doi: 10.1074/jbc.271.17.10073
  21. Lazarenko R, Geisler J, Bayliss D et al. D-chiro-inositol glycan stimulates insulin secretion in pancreatic b cells. Mol Cell Endocrinol 2014; 387 (1–2): 1–7. doi: 10.1016/j.mce.2014.02.004
  22. Hu Y, Zhao Y, Ren D et al. Hypoglycemic and hepatoprotective effects of D-chiro-inositol-enriched tartary buckwheat extract in high fructose-fed mice. Food Funct 2015; 6 (12): 3760–9. doi: 10.1039/c5fo00612k
  23. Fan C, Liang W, Wei M et al. Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Front Pharmacol 2020; 11: 354. doi: 10.3389/fphar.2020.00354
  24. Ostlund RE Jr, McGill JB, Herskowitz I et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci USA 1993; 90 (21): 9988–92. doi: 10.1073/pnas.90.21.9988
  25. Murphy A, Shamshirsaz A, Markovic D et al. Urinary Excretion of Myo-Inositol and D-Chiro-Inositol in Early Pregnancy Is Enhanced in Gravidas With Gestational Diabetes Mellitus. Reprod Sci 2016; 23 (3): 365–71. doi: 10.1177/1933719115602767
  26. La Marca A, Grisendi V, Dondi G et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2015; 31 (1): 52–6. doi: 10.3109/09513590.2014.964201
  27. Iuorno MJ, Jakubowicz DJ, Baillargeon JP et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8 (6): 417–23. doi: 10.4158/EP.8.6.417
  28. Nestler JE, Jakubowicz DJ, Reamer P et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340 (17): 1314–20. doi: 10.1056/NEJM199904293401703
  29. Baillargeon JP, Iuorno MJ, Jakubowicz DJ et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89 (1): 242–9. doi: 10.1210/jc.2003-030437
  30. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 2011; 27 (4): 256–62. doi: 10.3109/09513590.2010.538099
  31. Fonteles MC, Almeida MQ, Larner J. Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats. Horm Metab Res 2000; 32 (4): 129–32. doi: 10.1055/s-2007-978606
  32. Gluck G, Anguelova T, Heimark D, Larner J. Synergistic Effects of d-Chiro-Inositol and Manganese on Blood Glucose and Body Weight of Streptozotocin-Induced Diabetic Rats. Curr Bioactive Compounds 2010; 6: 90. doi: 10.2174/157340710791184831
  33. Dell’Edera D, Sarlo F, Allegretti A et al. The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. Biomed Rep 2017; 7 (2): 169–72. doi: 10.3892/br.2017.939
  34. Maurizi AR, Menduni M, Del Toro R et al. A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol 2017; 54 (4): 361–5. doi: 10.1007/s00592-016-0954-x
  35. Malvasi A, Casciaro F, Minervini MM et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci 2014; 18 (2): 270–4. PMID: 24488919.
  36. Cheng F, Han L, Xiao Y et al. D-chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCe-PI3K/AKT Pathway. J Agric Food Chem 2019; 67 (21): 5957–67. doi: 10.1021/acs.jafc.9b01253
  37. Zhao SS, Li NR, Zhao WL et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin 2018; 39 (2): 213–21. doi: 10.1038/aps.2017.98
  38. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011; 95 (8): 2515–6. doi: 10.1016/j.fertnstert.2011.05.027
  39. Laganà AS, Garzon S, Casarin J et al. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab 2018; 29 (11): 768–80. doi: 10.1016/j.tem.2018.09.001
  40. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29 (2): 300–5. doi: 10.2337/diacare.29.02.06.dc05-1070
  41. Ravanos K, Monastra G, Pavlidou T et al. Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci 2017; 21 (23): 5491–8. doi: 10.26355/eurrev_201712_13940
  42. Cogram P, Tesh S, Tesh J et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod 2002; 17 (9): 2451–8. doi: 10.1093/humrep/17.9.2451
  43. Nordio M, Basciani S, Camajani E. The 40: 1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci 2019; 23 (12): 5512–21. doi: 10.26355/eurrev_201906_18223
  44. Le Donne M, Metro D, Alibrandi A et al. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2019; 23 (5): 2293–301. doi: 10.26355/eurrev_201903_17278
  45. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012; 16 (5): 575–81. PMID: 22774396.
  46. Januszewski M, Issat T, Jakimiuk AA et al. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol 2019; 90 (1): 7–10. doi: 10.5603/GP.2019.0002
  47. Mendoza N, Diaz-Ropero MP, Aragon M et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2019; 35 (8): 695–700. doi: 10.1080/09513590.2019.1576620
  48. Mendoza N, Galan MI, Molina C et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol 2020; 36 (5): 398–401. doi: 10.1080/09513590.2019.1681959
  49. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol 2014; 30 (3): 205–8. doi: 10.3109/09513590.2013.860120
  50. Громова О.А., Торшин И.Ю., Андреева Е.Н. и др. Системно-биологический анализ ролей марганца в акушерстве и гинекологии: репродуктивное здоровье женщины, регуляция менструального цикла и профилактика пороков развития плода. Вопр. гинекологии, акушерства и перинатологии. 2020; 19 (1): 103–13. doi: 10.20953/1726-1678-2020-1-103-113
  51. [Gromova O.A., Torshin I.Yu., Andreeva E.N. et al. System-biological analysis of the roles of manganese in obstetrics and gynecology: reproductive health of women, regulation of the menstrual cycle and prevention of fetal malformations. Questions of Gynecology, Obstetrics and Perinatology. 2020; 19 (1): 103–13. doi: 10.20953/1726-1678-2020-1-103-113 (in Russian).]

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract - 46

PDF (Russian) - 0

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies